← Back to Search

Music Therapy for Alzheimer's Disease

N/A
Recruiting
Led By Joanne Loewy, DA, LCAT, MT-BC
Research Sponsored by Icahn School of Medicine at Mount Sinai
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months

Summary

This trial will compare the effects of music therapy experiences on memory and language in patients with Alzheimer's disease and Mild Cognitive Impairment.

Who is the study for?
This trial is for English-speaking individuals with Alzheimer's or mild cognitive impairment who have a study partner and can use a webcam or smartphone. They must be able to communicate verbally, live in the community, and not have significant health issues that could interfere with the study.
What is being tested?
The study compares home-based music therapy through singing (H3S), individualized music therapy (IMT), and an attention control group involving pleasant events without music. It aims to see how these affect memory, language, and quality of life over 12 months.
What are the potential side effects?
Since this trial involves non-invasive music therapy interventions, there are no direct medical side effects expected. However, participants may experience varying emotional responses to the therapy sessions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Activities of Daily Living (ADCS-ADL)
Clinician's Global Impression of Change (ADCS-CGIC)
Mini Mental Status Exam (MMSE)
+1 more
Secondary study objectives
The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)
Zarit Burden Interview

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Home-based MT through Supervised, Supported Singing (H3S)Experimental Treatment1 Intervention
Treatment arm 1
Group II: H3S and IMTExperimental Treatment2 Interventions
Treatment arm 2 received both Home-based Supervised, Supported Singing (H3S) and Individualized Music Therapy (IMT)
Group III: Attention Control (AtCon)Placebo Group1 Intervention
Comparison condition with comparable attention

Find a Location

Who is running the clinical trial?

Icahn School of Medicine at Mount SinaiLead Sponsor
914 Previous Clinical Trials
572,801 Total Patients Enrolled
Joanne Loewy, DA, LCAT, MT-BCPrincipal InvestigatorMount Sinai Beth Israel
1 Previous Clinical Trials
178 Total Patients Enrolled
Mary Sano, PhDPrincipal InvestigatorIcahn School of Medicine at Mount Sinai
5 Previous Clinical Trials
1,221 Total Patients Enrolled

Media Library

Home-based MT through Supervised, Supported Singing (H3S) Clinical Trial Eligibility Overview. Trial Name: NCT04666077 — N/A
Alzheimer's Disease Research Study Groups: Home-based MT through Supervised, Supported Singing (H3S), H3S and IMT, Attention Control (AtCon)
Alzheimer's Disease Clinical Trial 2023: Home-based MT through Supervised, Supported Singing (H3S) Highlights & Side Effects. Trial Name: NCT04666077 — N/A
Home-based MT through Supervised, Supported Singing (H3S) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04666077 — N/A
~9 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top